Core Viewpoint - Weigao Group (01066) announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Company Summary - The company plans to repurchase 340,000 shares at a total cost of HKD 1.8368 million [1]

Group 1 - The company, Weigao Group (01066.HK), announced a share buyback on November 6, 2023, spending HKD 1.8368 million to repurchase 340,000 shares at a price range of HKD 5.39 to 5.42 per share [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 山東威高集團醫用高分子製品股份有限公司 呈交日期： 2025年11月6日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01066 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 ...

Core Viewpoint - Goldman Sachs reports that Weigao's third-quarter revenue reached 3.26 billion yuan, representing a year-on-year growth of 2.6%, compared to flat growth in the first half of the year [1] Revenue Performance - The pharmaceutical packaging and general medical consumables business continues to face pressure due to insufficient sales growth to offset pricing pressures from volume-based procurement (VBP), particularly in the flushing syringe segment [1] - The growth rate of products used during surgeries is slower than expected in a weak macroeconomic environment [1] - In contrast, revenue from orthopedics, interventional therapy, and blood management businesses showed relatively strong growth [1] Financial Forecast Adjustments - Due to ongoing pricing pressures, Goldman Sachs has lowered its revenue and net profit forecasts for 2025 by 4.4% and 8.5%, respectively [1] - The full-year revenue is now expected to increase by 1.9% year-on-year, while profit is projected to decline by 7.8% [1] Target Price and Rating - The target price has been reduced from 7.8 HKD to 7.4 HKD, while maintaining a "Buy" rating [1]

Core Viewpoint - Goldman Sachs reported that Weigao Group (01066) experienced a revenue of 3.26 billion RMB in Q3, representing a year-on-year growth of 2.6%, compared to flat growth in the first half of the year [1] Revenue Performance - The pharmaceutical packaging and general medical consumables business continues to face pressure due to insufficient sales growth to offset the pricing pressure from volume-based procurement (VBP), particularly in the flushing syringe segment [1] - The growth rate of product promotion during surgeries is slower than expected in a weak macroeconomic environment [1] - Conversely, revenue from orthopedics, interventional therapy, and blood management businesses showed relatively strong growth [1] Forecast Adjustments - Due to ongoing pricing pressures, the firm has lowered its revenue and net profit forecasts for 2025 by 4.4% and 8.5%, respectively [1] - The current expectation for full-year revenue is a year-on-year increase of 1.9%, while profit is anticipated to decline by 7.8% [1] Target Price Revision - The target price has been reduced from 7.8 HKD to 7.4 HKD, while maintaining a "Buy" rating [1]

Core Viewpoint - Goldman Sachs reports that Weigao Group (01066) experienced a revenue of 3.26 billion RMB in Q3, reflecting a year-on-year growth of 2.6%, which is flat compared to the first half of the year [1] Revenue Performance - The pharmaceutical packaging and general medical consumables business continues to face pressure due to insufficient sales growth to offset the pricing pressure from volume-based procurement (VBP), particularly in the flushing syringe segment [1] - The growth rate of products during surgeries is slower than expected in a weak macroeconomic environment [1] - Conversely, revenue growth in orthopedics, interventional therapy, and blood management segments is relatively strong [1] Forecast Adjustments - Due to ongoing pricing pressures, the company has revised its revenue and net profit forecasts for 2025 down by 4.4% and 8.5%, respectively [1] - The new expectation for full-year revenue is a year-on-year increase of 1.9%, while profit is anticipated to decline by 7.8% [1] Target Price and Rating - The target price has been reduced from 7.8 HKD to 7.4 HKD, while maintaining a "Buy" rating [1]

Core Points - The Ministry of Industry and Information Technology and the National Medical Products Administration have announced the second batch of selected units for the innovative task of biomedical materials, with a total of 86 units selected across 35 categories [2] - Five companies from Shandong have been selected, including Weihai Weigao Blood Collection Consumables Co., Ltd., Qingdao Haier Biomedical Co., Ltd., Shandong Guyu Spring Biotechnology Co., Ltd., Shandong Weigao Group Medical Polymer Products Co., Ltd., and Shandong Guocer Functional Materials Co., Ltd. [2] - The selected companies are focusing on various innovative materials such as polyethylene terephthalate, non-phthalate plasticizers, polyester-polyethylene glycol copolymers, high-end polypropylene, and 3D printing zirconia ceramic ink [2] Industry Support - Local industrial and information authorities will collaborate with drug supervision departments to enhance tracking and support for the selected units and projects [2] - There will be prioritized allocation of resources such as project land, energy, and pollution discharge indicators for the selected units [2] - After completing the innovation tasks within three years, the Ministry of Industry and Information Technology and the National Medical Products Administration will commission professional institutions to evaluate and select the outstanding units, with a limit of two winners per product [2]

Major Events - Xiaoma Zhixing-W (02026) has set the share price for its offering at HKD 139 [1] - Boleton (01333) has entered into a strategic cooperation with Fujian Rixin, focusing on autonomous driving for mining transportation [1] - Zhaojin Mining (01818) has signed a strategic cooperation memorandum with Ant Group [1] - Yimai Sunshine (02522) subsidiary has signed a data co-construction cooperation agreement with Beijing Xianxing District and Beijing Computing Power [1] - Yaojie Ankang-B (02617) has reached a project cooperation agreement with Neurocrine [1] - Heng Rui Pharmaceutical (01276) plans to include HRS-5965 capsules in the priority review process [1] Financial Data - XPeng Motors-W (09868) delivered 42,013 smart electric vehicles in October, a year-on-year increase of 76%, setting a new monthly delivery record [1] - Fuwai Group (01828) reported a sales revenue of USD 1.935 billion for the first three quarters, a year-on-year increase of 37% [1] - Shenzhen Holdings (00604) recorded total contract sales of approximately CNY 9.838 billion for the first three quarters, a year-on-year increase of 24% [1] - Weigao Group (01066) reported third-quarter revenue of approximately CNY 3.26 billion, a year-on-year growth of about 2.6% [1]

Core Viewpoint - Weigao Group (01066) announced a share repurchase of 300,400 shares scheduled for November 3, 2025 [1] Summary by Category Company Actions - Weigao Group plans to repurchase a total of 300,400 shares [1]

威高股份(01066)公布，2025年11月3日回购30.04万股股份。 ...